83 FR 14859 - Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

Federal Register Volume 83, Issue 67 (April 6, 2018)

Page Range		14859-14859
FR Document		2018-07053

Federal Register, Volume 83 Issue 67 (Friday, April 6, 2018)

[Federal Register Volume 83, Number 67 (Friday, April 6, 2018)]
[Notices]
[Page 14859]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-07053]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Director, Management 
Analysis and Services Office, CDC, pursuant to Public Law 92-463. The 
grant applications and the discussions could disclose confidential 
trade secrets or commercial property such as patentable material, and 
personal information concerning individuals associated with the grant 
applications, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: Disease, Disability, and Injury Prevention 
and Control Special Emphasis Panel (SEP)--CK18-001, Epicenters for 
the Prevention of Healthcare-Associated Infections (HAIs); Cycle II 
Multicenter Program Studies and CK18-003, Determining and Monitoring 
Health Conditions Among US-Bound Refugees and Other Globally Mobile 
Populations.
    Date: May 9, 2018.
    Time: 10:00 a.m.-3:00 p.m., EDT.
    Place: Teleconference.
    Agenda: To review and evaluate grant applications.
    For Further Information Contact: Gregory Anderson, M.S., M.P.H., 
Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop E60, 
Atlanta, Georgia 30329, (404) 718-8833, [email protected].
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

Elaine Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2018-07053 Filed 4-5-18; 8:45 am]
 BILLING CODE 4163-18-P

Federal Register / Vol. 83, No. 67 / Friday, April 6, 2018 / Notices 14859

Leroy A. Richardson, DEPARTMENT OF HEALTH AND DEPARTMENT OF HEALTH AND
Chief, Information Collection Review Office, HUMAN SERVICES HUMAN SERVICES
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the Centers for Disease Control and Food and Drug Administration
Director, Centers for Disease Control and Prevention
Prevention. [Docket No. FDA–2018–N–0791]
[FR Doc. 2018–07016 Filed 4–5–18; 8:45 am] Notice of Closed Meeting Exposure-Response Analysis in Drug
BILLING CODE 4163–18–P Development and Regulatory Decision
Pursuant to section 10(d) of the Making; Establishment of a Public
Federal Advisory Committee Act, as Docket; Request for Comments
DEPARTMENT OF HEALTH AND amended, notice is hereby given of the
HUMAN SERVICES following meeting. AGENCY: Food and Drug Administration,
HHS.
Centers for Disease Control and The meeting will be closed to the ACTION: Notice; establishment of a
Prevention public in accordance with the public docket; request for comments.
provisions set forth in sections
Notice of Closed Meeting 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., SUMMARY: The Prescription Drug User
as amended, and the Determination of Fee Act of 2017 (PDUFA VI), part of the
Pursuant to section 10(d) of the the Director, Management Analysis and FDA Reauthorization Act of 2017
Federal Advisory Committee Act, as Services Office, CDC, pursuant to Public (FDARA, highlights the goal of
amended, notice is hereby given of the Law 92–463. The grant applications and advancing model-informed drug
following meeting. the discussions could disclose development (MIDD). Exposure-
The meeting will be closed to the confidential trade secrets or commercial response analysis is a MIDD strategy
public in accordance with the that has been used in drug development
property such as patentable material,
provisions set forth in sections and regulatory decision making. The
and personal information concerning
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Food and Drug Administration (FDA or
individuals associated with the grant
as amended, and the Determination of Agency) is opening a docket to receive
applications, the disclosure of which public comments on experience
the Director, Management Analysis and would constitute a clearly unwarranted
Services Office, CDC, pursuant to Public leveraging exposure-response analysis
invasion of personal privacy. since publishing the guidance for
Law 92–463. The grant applications and
the discussions could disclose Name of Committee: Disease, Disability, industry (GFI) entitled ‘‘Exposure-
confidential trade secrets or commercial and Injury Prevention and Control Special Response Relationships—Study Design,
property such as patentable material, Emphasis Panel (SEP)—CK18–001, Data Analysis, and Regulatory
and personal information concerning Epicenters for the Prevention of Healthcare- Applications,’’ which was announced in
individuals associated with the grant Associated Infections (HAIs); Cycle II the Federal Register on May 6, 2003.
applications, the disclosure of which Multicenter Program Studies and CK18–003, Specifically, the Agency wants to
would constitute a clearly unwarranted Determining and Monitoring Health identify areas of scientific policy that
invasion of personal privacy. Conditions Among US-Bound Refugees and may need further clarity or elaboration,
Other Globally Mobile Populations. as well as any obstacles that prevent use
Name of Committee: Disease, Disability, Date: May 9, 2018. of exposure-response analyses in drug
and Injury Prevention and Control Special Time: 10:00 a.m.–3:00 p.m., EDT.
Emphasis Panel (SEP)—RFA–CE–18–002,
development and regulatory review.
Place: Teleconference. DATES: To ensure that the Agency
Evaluation of Policies for the Primary
Agenda: To review and evaluate grant considers your input, submit either
Prevention of Multiple Forms of Violence.
Dates: May 23, 2018 and May 24, 2018. applications. electronic or written comments by July
Time: 9:00 a.m.–5:00 p.m., EDT. For Further Information Contact: Gregory 5, 2018.
Place: DoubleTree by Hilton Hotel Anderson, M.S., M.P.H., Scientific Review
ADDRESSES: You may submit comments
Atlanta—Buckhead, 3342 Peachtree Road NE, Officer, CDC, 1600 Clifton Road NE, Mailstop
as follows. Electronic comments must
Atlanta, GA 30326. E60, Atlanta, Georgia 30329, (404) 718–8833,
Agenda: To review and evaluate grant gca5@cdc.gov.
be submitted on or before July 5, 2018.
applications. The Director, Management Analysis and
Comments received by mail/hand
For Further Information Contact: Mikel L. Services Office, has been delegated the
delivery/courier (for written/paper
Walters, M.A., Ph.D., Scientific Review authority to sign Federal Register notices submissions) will be considered timely
Official, NCIPC, CDC, 4770 Buford Highway pertaining to announcements of meetings and if they are postmarked or the delivery
NE, Mailstop F–63, Atlanta, Georgia 30341, other committee management activities, for date service acceptance receipt is on or
Telephone: (404)639–0913; Email: mwalters@ before that date:
both the Centers for Disease Control and
cdc.gov.
Prevention and the Agency for Toxic Electronic Submissions
The Director, Management Analysis and
Services Office, has been delegated the Substances and Disease Registry.
Submit electronic comments in the
authority to sign Federal Register notices Elaine Baker, following way:
pertaining to announcements of meetings and
Director, Management Analysis and Services • Federal eRulemaking Portal:
other committee management activities, for https://www.regulations.gov. Follow the
both the Centers for Disease Control and Office, Centers for Disease Control and
Prevention. instructions for submitting comments.
Prevention and the Agency for Toxic
Substances and Disease Registry. [FR Doc. 2018–07053 Filed 4–5–18; 8:45 am] Comments submitted electronically,
daltland on DSKBBV9HB2PROD with NOTICES

including attachments, to https://
BILLING CODE 4163–18–P
Elaine Baker, www.regulations.gov will be posted to
Director, Management Analysis and Services the docket unchanged. Because your
Office, Centers for Disease Control and comment will be made public, you are
Prevention. solely responsible for ensuring that your
[FR Doc. 2018–07051 Filed 4–5–18; 8:45 am] comment does not include any
BILLING CODE 4163–18–P confidential information that you or a

VerDate Sep<11>2014 20:38 Apr 05, 2018 Jkt 244001 PO 00000 Frm 00018 Fmt 4703 Sfmt 4703 E:\FR\FM\06APN1.SGM 06APN1

Document Created: 2018-11-01 09:15:34
Document Modified: 2018-11-01 09:15:34

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		May 9, 2018.
Contact		Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop E60, Atlanta, Georgia 30329, (404) 718-8833, [email protected]
FR Citation		83 FR 14859

83 FR 14859 - Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESCenters for Disease Control and Prevention

Federal Register Volume 83, Issue 67 (April 6, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention